CD8A and neoplasm: To evaluate whether the intratumoral combination treatment induced specific antitumor CD8+ T cells responses, we purified CD8+ T cells in tumor draining lymph node (DLN), spleen and tumor tissue in different time points after treatments, and then re-stimulated the CD8+ T cells with LLC or B16F10 tumor cells.